Search research articles
Contact Us
Filters
Showing results (161-170 of 189) with videos related to
Page
of 19
Sort By:
The Journal of Experimental Medicine
|
February 24, 2000
Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
E Jäger, D Jäger, J Karbach, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 17, 2009
Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
U Petrausch, P Samaras, P Veit-Haibach, et al.
Annals of Surgical Oncology
|
January 6, 2011
Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases
Panagiotis Samaras, S Breitenstein, S R Haile, et al.
British Journal of Cancer
|
June 21, 2007
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
A Atmaca, S-E Al-Batran, A Maurer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2010
Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy
U Petrausch, P Samaras, S R Haile, et al.
International Journal of Cancer
|
May 8, 2000
Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides
E Jäger, M Maeurer, H Höhn, et al.
British Journal of Cancer
|
May 11, 2006
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
S-E Al-Batran, J Bischoff, G von Minckwitz, et al.
The Journal of Experimental Medicine
|
February 7, 1998
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
E Jäger, Y T Chen, J W Drijfhout, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 6, 2000
Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL
J L Chen, P R Dunbar, U Gileadi, et al.
British Journal of Cancer
|
March 5, 2004
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
I Bleumer, A Knuth, E Oosterwijk, et al.
Page
of 19
Search research articles
Search
Showing results (161-170 of 189) with videos related to
Sort By:
Page
of 19
The Journal of Experimental Medicine
|
February 24, 2000
Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma
E Jäger, D Jäger, J Karbach, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
November 17, 2009
Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up?
U Petrausch, P Samaras, P Veit-Haibach, et al.
Annals of Surgical Oncology
|
January 6, 2011
Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases
Panagiotis Samaras, S Breitenstein, S R Haile, et al.
British Journal of Cancer
|
June 21, 2007
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
A Atmaca, S-E Al-Batran, A Maurer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 9, 2010
Risk-adapted FDG-PET/CT-based follow-up in patients with diffuse large B-cell lymphoma after first-line therapy
U Petrausch, P Samaras, S R Haile, et al.
International Journal of Cancer
|
May 8, 2000
Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides
E Jäger, M Maeurer, H Höhn, et al.
British Journal of Cancer
|
May 11, 2006
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
S-E Al-Batran, J Bischoff, G von Minckwitz, et al.
The Journal of Experimental Medicine
|
February 7, 1998
Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes
E Jäger, Y T Chen, J W Drijfhout, et al.
Journal of Immunology (Baltimore, Md. : 1950)
|
July 6, 2000
Identification of NY-ESO-1 peptide analogues capable of improved stimulation of tumor-reactive CTL
J L Chen, P R Dunbar, U Gileadi, et al.
British Journal of Cancer
|
March 5, 2004
A phase II trial of chimeric monoclonal antibody G250 for advanced renal cell carcinoma patients
I Bleumer, A Knuth, E Oosterwijk, et al.
Page
of 19